Express Mail Label No.: EV978766854US

Date of Deposit: January 15, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Jeffers et al.

SERIAL NUMBER:

09/992,840

EXAMINER:

J. Seharaseyon, Ph.D.

FILING DATE:

November 6, 2001

ART UNIT:

1647

Attorney Docket No. 15966-557 A (Cura 57 A)

For:

TREATMENT OF INFLAMMATORY BOWEL DISEASE USING GROWTH FACTORS

Mail Stop Sequence

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

January 16, 2007

Boston, Massachusetts

STATEMENT IN SUPPORT

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. The sequence listing is supported by the specification and references incorporated therein. Therefore, no new matter is added at this time.

Respectfully submitted,

Jennifer A. Karnakis, Reg. No. 53,097

Attorney for Applicants c/o MINTZ, LEVIN Tel: (617) 542-6000

Fax: (617) 542-2241 Customer No. 55111

TRA 2243959v.1

Express Mail Label No.: EV978766854US

Date of Deposit: January 16, 2007

Attorney Docket No.: 15966-557 A (CURA 57A)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS: Jeffers et al.

XIAL NUMBER: 09/992,840 EXA

EXAMINER: J. Seharaseyon, Ph.D.

FILING DATE: November 6, 2001 ART UNIT: 1647

FOR: TREATMENT OF INFLAMMATORY BOWEL DISEASE USING GROWTH FACTORS

Mail Stop Sequence

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

January 16, 2007 Boston, Massachusetts

RESPONSE TO NOTICE TO COMPLY

In response to the Notice to Comply (the "Notice") mailed November 14, 2006, Applicants submit herein electronic and paper copies of the Sequence Listing (1 disk, 14 pages), a Statement in Support of Computer Readable Form Submission (1 page), a Preliminary Amendment (3 pages), a Petition for a One-Month Extension of Time (1 page), a check (Check No. 23685) in the amount of \$60.00 to cover the extension fee; and a copy of the Notice to Comply (4 pages).

With a one-month extension, this filing is due on or before Tuesday, January 16, 2007 (January 14, 2007 being a Sunday and Monday, January 15, 2007 being a federal holiday). Applicants believe no additional fees are due in connection with this filing. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below. The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-557A (Cura 57A).

Respectfully submitted,


vor R. Elrifi, Reg. No. 39,52

Atterney(s) for Applicants


MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 55111 Tel: (617) 542-6000 Fax: (617) 542-2241



Please find below and/or attached an Office communication concerning this application or proceeding.









UNITED STATES D' `ARTMENT OF COMMERCE U.S. Patent and Trauemark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR I PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
09/992840)	Jeffens etal		
			EXAMINER	
			J. 9	sehavaseyon.
. 1.			ART UNIT	PAPER
			1647	20061110

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- 1. Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. Mailed to:

Mail Stop SequenceCommissioner for Patents

P.O. Box 22313 1450

Alexandria, VA 22313 1450

3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:

U.S. Patent and Trademark Office

Mail Stop Sequence

Customer Window

Randolph Building

401 Dulaney Street

Alexandria, VA 22314.

PTO-90C (Rev.04-03)

Any inquiry concerning this communication or earlier communications from the examiner s. ald be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00.If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jesalheesan Schorasayon, Palent Examin,

Application No. Applicant(s) JEFFERS ET AL. 09/992.840 Notice to Comply JAN 1 6 2007 **Art Unit** Examiner 1647 Jegatheesan Seharaseyon

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The	e nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the uirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
☒	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). I the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1 1998) and 1211 OG 82 (June 23, 1998).
Ø	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
\boxtimes	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
□	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). The correct SEQ ID NO:2 is present in the paper copy of the of the sequence listing only. Therefore a search of the correct sequence is not possible.
	7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☑ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

Patentin Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY